Toxicities of targeted therapies and their management in renal cancer: methodology of guidelines

被引：1
作者：
Escudier, Bernard [1 ]
Joly, Florence [2 ]
Soria, Jean-Charles [3 ]
机构：
[1] Inst Gustave Roussy, Dept Med, F-94805 Villejuif, France
[2] Ctr Francois Baclesse, F-14076 Caen 05, France
[3] Inst Gustave Roussy, SITEP, F-94805 Villejuif, France
来源：
BULLETIN DU CANCER | 2011年 / 98卷
关键词：
renal cell carcinoma; immunotherapy; nephrectomy; anti-angiogenesis; mammalian target of rapamycin; guidelines; toxicities; CELL CARCINOMA; INTERFERON-ALPHA; DOUBLE-BLIND; TEMSIROLIMUS; SUNITINIB;
D O I：
10.1684/bdc.2011.1444
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Advanced renal cell carcinoma (RCC) is associated with a poor prognosis and is refractory to standard chemotherapy. Recent progress in the understanding of molecular biology and pathogenesis of renal cell cancer has been translated into the development of new therapeutic strategies. The management of metastatic RCC has been revolutionized with the development of targeted molecular therapies against VEGF-VEGFR and mTOR. Randomized phase III clinical trials demonstrated clinical benefit for patients with advanced RCC in overall survival and progression free survival. Guidelines for the management of side effects induced by these targeted therapies seem to be warranted. Delta
引用
收藏
页码：S3 / S6
页数：4
相关论文
共 8 条
[1]   Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma [J].
Bhojani, Naeem ;
Jeldres, Claudio ;
Patard, Jean-Jacques ;
Perrotte, Paul ;
Suardi, Nazareno ;
Hutterer, Georg ;
Patenaude, Francois ;
Oudard, Stephane ;
Karakiewicz, Pierre I. .
EUROPEAN UROLOGY, 2008, 53 (05) :917-930
[2]   Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial [J].
Escudier, Bernard ;
Pluzanska, Anna ;
Koralewski, Piotr ;
Ravaud, Alain ;
Bracarda, Sergio ;
Szczylik, Cezary ;
Chevreau, Christine ;
Filipek, Marek ;
Melichar, Bohuslav ;
Bajetta, Emilio ;
Gorbunova, Vera ;
Bay, Jacques-Olivier ;
Bodrogi, Istvan ;
Jagiello-Gruszfeld, Agnieszka ;
Moore, Nicola .
LANCET, 2007, 370 (9605) :2103-2111
[3]   Sorafenib in advanced clear-cell renal-cell carcinoma [J].
Escudier, Bernard ;
Eisen, Tim ;
Stadler, Walter M. ;
Szczylik, Cezary ;
Oudard, Stephane ;
Siebels, Michael ;
Negrier, Sylvie ;
Chevreau, Christine ;
Solska, Ewa ;
Desai, Apurva A. ;
Rolland, Frederic ;
Demkow, Tomasz ;
Hutson, Thomas E. ;
Gore, Martin ;
Freeman, Scott ;
Schwartz, Brian ;
Shan, Minghua ;
Simantov, Ronit ;
Bukowski, Ronald M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (02) :125-134
[4]   Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma [J].
Hudes, Gary ;
Carducci, Michael ;
Tomczak, Piotr ;
Dutcher, Janice ;
Figlin, Robert ;
Kapoor, Anil ;
Staroslawska, Elzbieta ;
Sosman, Jeffrey ;
McDermott, David ;
Bodrogi, Istvan ;
Kovacevic, Zoran ;
Lesovoy, Vladimir ;
Schmidt-Wolf, Ingo G. H. ;
Barbarash, Olga ;
Gokmen, Erhan ;
O'Toole, Timothy ;
Lustgarten, Stephanie ;
Moore, Laurence ;
Motzer, Robert J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (22) :2271-2281
[5]   Efficacy of everolimus in advanced renal cell carcinoma:: a double-blind, randomised, placebo-controlled phase III trial [J].
Motzer, Robert J. ;
Escudier, Bernard ;
Oudard, Stephane ;
Hutson, Thomas E. ;
Porta, Camillo ;
Bracarda, Sergio ;
Gruenwald, Viktor ;
Thompson, John A. ;
Figlin, Robert A. ;
Hollaender, Norbert ;
Urbanowitz, Gladys ;
Berg, William J. ;
Kay, Andrea ;
Lebwohl, David ;
Ravaud, Alain .
LANCET, 2008, 372 (9637) :449-456
[6]   Sunitinib versus interferon alfa in metastatic renal-cell carcinoma [J].
Motzer, Robert J. ;
Hutson, Thomas E. ;
Tomczak, Piotr ;
Michaelson, M. Dror ;
Bukowski, Ronald M. ;
Rixe, Olivier ;
Oudard, Stephane ;
Negrier, Sylvie ;
Szczylik, Cezary ;
Kim, Sindy T. ;
Chen, Isan ;
Bycott, Paul W. ;
Baum, Charles M. ;
Figlin, Robert A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (02) :115-124
[7]   Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206 [J].
Rini, Brian I. ;
Halabi, Susan ;
Rosenberg, Jonathan E. ;
Stadler, Walter M. ;
Vaena, Daniel A. ;
Ou, San-San ;
Archer, Laura ;
Atkins, James N. ;
Picus, Joel ;
Czaykowski, Piotr ;
Dutcher, Janice ;
Small, Eric J. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (33) :5422-5428
[8]   Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial [J].
Sternberg, Cora N. ;
Davis, Ian D. ;
Mardiak, Jozef ;
Szczylik, Cezary ;
Lee, Eunsik ;
Wagstaff, John ;
Barrios, Carlos H. ;
Salman, Pamela ;
Gladkov, Oleg A. ;
Kavina, Alexander ;
Zarba, Juan J. ;
Chen, Mei ;
McCann, Lauren ;
Pandite, Lini ;
Roychowdhury, Debasish F. ;
Hawkins, Robert E. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (06) :1061-1068
1